Posttransplant cyclophosphamide contributes to the impairment of the graft-versus-leukemia effect and the amelioration of graft-versus-host disease with the suppression of alloreactive T cells in a murine stem cell transplant model

Posttransplant cyclophosphamide (PTCy) is effective as prophylaxis for graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT) [1-5]. GVHD is still a major severe complication after HSCT; thus, the control of GVHD plays an essential role in improving survival after HSCT. Allogeneic HSCT is a curative treatment for patients with hematologic malignancy through the graft-versus-leukemia (GVL) effect, which is an anti-leukemia effect of donor-derived alloreactive T cells after HSCT [6].
Source: Experimental Hematology - Category: Hematology Authors: Source Type: research